02087nam a2200265 4500 ESSALUD 20260902151624.0 ta t pe ||||| |||| 00| 0 spa d BMG eng Srivastava, Deepak Autor 54430 Remuscularizing the failing human heart páginas: 2055-2058 Heart failure with reduced ejection fraction remains a progressive and ultimately lethal condition for millions of patients worldwide. Although current therapies prolong survival and reduce symptoms, they do not address the fundamental pathologic substrate: the irreversible loss of cardiomyocytes and their replacement with fibrotic scar. Patients with advanced heart failure — particularly those with ischemic heart failure — may lose as many as a billion cardiomyocytes, and the annual mortality among patients with advanced heart failure is approximately 50%. Among patients with heart failure of any severity, the inability of the heart to regenerate muscle and the physiological stress of a dilated failing heart result in a 5-year mortality of approximately 50%. For decades, the notion of replacing lost cells — of truly remuscularizing the human heart — has been a central aspiration of regenerative medicine. Major approaches currently being advanced for cardiac regeneration (see Key Concepts) include unlocking cell division in resident cardiomyocytes, reprogramming of resident cardiac fibroblasts into induced cardiomyocytes, and transplantation of pluripotent stem-cell–derived cardiomyocytes, each with a goal of creating more contractile units. CARDIOLOGÍA GENERAL 53638 CARDIOMIOPATÍA 37409 MIOCARDITIS 38353 PERICARDITIS 39732 CIRUGÍA CARDIOVASCULAR 53947 INSUFICIENCIA CARDIACA 11699 TRASPLANTE 7847 22717 22665 Massachusetts NEJM Group NEJM013 The New England Journal of Medicine ESSALUD 0028-4793 ARTICULOS 2026-08-28 sqb 22893 22893